Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Dec 1;57(23):3429-3432.
doi: 10.2169/internalmedicine.0999-18. Epub 2018 Aug 10.

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib

Affiliations
Free PMC article
Case Reports

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib

Mitsuo Sato et al. Intern Med. .
Free PMC article

Abstract

Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.

Keywords: EGFR mutation; afatinib; erlotinib; squamous cell carcinoma transformation.

Figures

Figure.
Figure.
(A) The clinical course of the present case shown by images of serial computed tomography and the treatment regimens administered. A rebiopsy with a core needle was performed from a metastatic lesion at the right latissimus dorsi muscle (white arrow). (B) The histopathological results demonstrate transformation from adenocarcinoma to squamous cell carcinoma (SCC). Cell blocks before treatment initiation showing adenocarcinoma, as characterized by malignant epithelial cells immunohistochemically positive for thyroid transcription factor-1 (TTF1) and negative for p40. A core needle biopsy after erlotinib and other treatment regimens showing an SCC, as characterized by keratin pearl formation (Hematoxylin and Eosin staining) as well as an immunohistochemical staining pattern indicative of SCC (p40-positive and TTF-1-almost-negative). CBDCA: carboplatin, PEM: pemetrexed, DTX: docetaxel, RT: radiation therapy

Similar articles

See all similar articles

Cited by 1 article

References

    1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. - PubMed
    1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. - PubMed
    1. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26, 2011. - PMC - PubMed
    1. Scher KS, Saldivar JS, Fishbein M, Marchevsky A, Reckamp KL. EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. J Natl Compr Canc Netw 11: 1040-1044, 2013. - PubMed
    1. Hsieh MS, Jhuang JY, Hua SF, Chou YH. Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment. Ann Thorac Surg 99: 316-319, 2015. - PubMed

Publication types

MeSH terms

Feedback